---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-317685"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2021-11-03T23:59:59+00:00"
generated_at: "2026-06-28T13:51:02.747897+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Agios Q3 net loss $88.8M; mitapivat gets FDA Priority Review with PDUFA Feb 17, 2022

## Summary
- Net loss $88.8M vs $99.0M in Q3 2020; R&D $64.0M up from $51.9M on trial start-up costs.
- Cash $1.4B; expects to fund operations through cash-flow positivity without equity raise.
- FDA granted Priority Review for mitapivat in PK deficiency; PDUFA date Feb. 17, 2022.
- Initiated Phase 3 ENERGIZE and ENERGIZE-T for thalassemia; plan to start RISE UP sickle cell study by year-end.
- Repurchased 5.3M shares at $47.94 avg; $800M+ of $1.2B buyback completed.

## SEC filing metadata
- accession: 0001193125-21-317685
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2021-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000119312521317685/0001193125-21-317685-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000119312521317685/d199842d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-317685
- JSON: https://secwatch.observer/filing/0001193125-21-317685.json
- Plain text: https://secwatch.observer/filing/0001193125-21-317685.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.